Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection

G. Gaipa, G. Basso, O. Maglia, V. Leoni, A. Faini, G. Cazzaniga, C. Bugarin, M. Veltroni, B. Michelotto, R. Ratei, T. Coliva, M. G. Valsecchi, A. Biondi, M. N. Dworzak

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Assessment of minimal residual disease (MRD) by flow cytometry is considered to be based on the reproducibility of the leukemic immunophenotype detected at diagnosis. However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment. Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol. Quantitative expression of seven antigens useful in MRD monitoring was studied at diagnosis and compared to that measured at different time points of remission induction therapy. Downmodulation in the expression of CD10 and CD34 occurred at follow-up. By contrast, upmodulation of CD19, CD20, CD45RA, and CD11a was observed, while the expression of CD58 remained stable. Despite this, we could unambiguously discriminate leukemic cells from normal residual B cells. This holds true when bone marrow (BM) samples from similarly treated T-ALL patients, but not from healthy donors, were used as reference. Our results indicate that immunophenotypic modulation occurs in ALL during the early phases of BFM-type protocols. However, the accuracy of MRD detection by flow cytometry seems not negatively affected if adequate analysis protocols are employed. Investigators should take this phenomenon into account in order to avoid pitfalls in flow cytometric MRD studies.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalLeukemia
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmaceutical Preparations
Flow Cytometry
Remission Induction
B-Lymphoid Precursor Cells
Surface Antigens
B-Lymphocytes
Bone Marrow
Research Personnel
Tissue Donors
Antigens
Therapeutics

Keywords

  • ALL
  • Flow cytometry
  • Immunophenotype
  • Minimal residual disease
  • Modulation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Drug-induced immunophenotypic modulation in childhood ALL : Implications for minimal residual disease detection. / Gaipa, G.; Basso, G.; Maglia, O.; Leoni, V.; Faini, A.; Cazzaniga, G.; Bugarin, C.; Veltroni, M.; Michelotto, B.; Ratei, R.; Coliva, T.; Valsecchi, M. G.; Biondi, A.; Dworzak, M. N.

In: Leukemia, Vol. 19, No. 1, 01.2005, p. 49-56.

Research output: Contribution to journalArticle

Gaipa, G, Basso, G, Maglia, O, Leoni, V, Faini, A, Cazzaniga, G, Bugarin, C, Veltroni, M, Michelotto, B, Ratei, R, Coliva, T, Valsecchi, MG, Biondi, A & Dworzak, MN 2005, 'Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection', Leukemia, vol. 19, no. 1, pp. 49-56. https://doi.org/10.1038/sj.leu.2403559
Gaipa, G. ; Basso, G. ; Maglia, O. ; Leoni, V. ; Faini, A. ; Cazzaniga, G. ; Bugarin, C. ; Veltroni, M. ; Michelotto, B. ; Ratei, R. ; Coliva, T. ; Valsecchi, M. G. ; Biondi, A. ; Dworzak, M. N. / Drug-induced immunophenotypic modulation in childhood ALL : Implications for minimal residual disease detection. In: Leukemia. 2005 ; Vol. 19, No. 1. pp. 49-56.
@article{ad4b80434cc54302bc5d4aa2060532ab,
title = "Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection",
abstract = "Assessment of minimal residual disease (MRD) by flow cytometry is considered to be based on the reproducibility of the leukemic immunophenotype detected at diagnosis. However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment. Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol. Quantitative expression of seven antigens useful in MRD monitoring was studied at diagnosis and compared to that measured at different time points of remission induction therapy. Downmodulation in the expression of CD10 and CD34 occurred at follow-up. By contrast, upmodulation of CD19, CD20, CD45RA, and CD11a was observed, while the expression of CD58 remained stable. Despite this, we could unambiguously discriminate leukemic cells from normal residual B cells. This holds true when bone marrow (BM) samples from similarly treated T-ALL patients, but not from healthy donors, were used as reference. Our results indicate that immunophenotypic modulation occurs in ALL during the early phases of BFM-type protocols. However, the accuracy of MRD detection by flow cytometry seems not negatively affected if adequate analysis protocols are employed. Investigators should take this phenomenon into account in order to avoid pitfalls in flow cytometric MRD studies.",
keywords = "ALL, Flow cytometry, Immunophenotype, Minimal residual disease, Modulation",
author = "G. Gaipa and G. Basso and O. Maglia and V. Leoni and A. Faini and G. Cazzaniga and C. Bugarin and M. Veltroni and B. Michelotto and R. Ratei and T. Coliva and Valsecchi, {M. G.} and A. Biondi and Dworzak, {M. N.}",
year = "2005",
month = "1",
doi = "10.1038/sj.leu.2403559",
language = "English",
volume = "19",
pages = "49--56",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Drug-induced immunophenotypic modulation in childhood ALL

T2 - Implications for minimal residual disease detection

AU - Gaipa, G.

AU - Basso, G.

AU - Maglia, O.

AU - Leoni, V.

AU - Faini, A.

AU - Cazzaniga, G.

AU - Bugarin, C.

AU - Veltroni, M.

AU - Michelotto, B.

AU - Ratei, R.

AU - Coliva, T.

AU - Valsecchi, M. G.

AU - Biondi, A.

AU - Dworzak, M. N.

PY - 2005/1

Y1 - 2005/1

N2 - Assessment of minimal residual disease (MRD) by flow cytometry is considered to be based on the reproducibility of the leukemic immunophenotype detected at diagnosis. However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment. Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol. Quantitative expression of seven antigens useful in MRD monitoring was studied at diagnosis and compared to that measured at different time points of remission induction therapy. Downmodulation in the expression of CD10 and CD34 occurred at follow-up. By contrast, upmodulation of CD19, CD20, CD45RA, and CD11a was observed, while the expression of CD58 remained stable. Despite this, we could unambiguously discriminate leukemic cells from normal residual B cells. This holds true when bone marrow (BM) samples from similarly treated T-ALL patients, but not from healthy donors, were used as reference. Our results indicate that immunophenotypic modulation occurs in ALL during the early phases of BFM-type protocols. However, the accuracy of MRD detection by flow cytometry seems not negatively affected if adequate analysis protocols are employed. Investigators should take this phenomenon into account in order to avoid pitfalls in flow cytometric MRD studies.

AB - Assessment of minimal residual disease (MRD) by flow cytometry is considered to be based on the reproducibility of the leukemic immunophenotype detected at diagnosis. However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment. Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol. Quantitative expression of seven antigens useful in MRD monitoring was studied at diagnosis and compared to that measured at different time points of remission induction therapy. Downmodulation in the expression of CD10 and CD34 occurred at follow-up. By contrast, upmodulation of CD19, CD20, CD45RA, and CD11a was observed, while the expression of CD58 remained stable. Despite this, we could unambiguously discriminate leukemic cells from normal residual B cells. This holds true when bone marrow (BM) samples from similarly treated T-ALL patients, but not from healthy donors, were used as reference. Our results indicate that immunophenotypic modulation occurs in ALL during the early phases of BFM-type protocols. However, the accuracy of MRD detection by flow cytometry seems not negatively affected if adequate analysis protocols are employed. Investigators should take this phenomenon into account in order to avoid pitfalls in flow cytometric MRD studies.

KW - ALL

KW - Flow cytometry

KW - Immunophenotype

KW - Minimal residual disease

KW - Modulation

UR - http://www.scopus.com/inward/record.url?scp=19944428207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428207&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403559

DO - 10.1038/sj.leu.2403559

M3 - Article

C2 - 15538405

AN - SCOPUS:19944428207

VL - 19

SP - 49

EP - 56

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -